Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.68
-0.02 (-0.19%)
Oct 6, 2026, 1:56 PM EDT - Market open
Zevra Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Zevra Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $25. The average 1-year stock price forecast is 134.08% higher than the current stock price, while the lowest is $20 (+87.27%) and the highest is $35 (+227.72%).
Price Target: $25 (+134.08%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 30, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $26 | Buy | Maintains | $26 | +143.45% | Sep 21, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $20 | Buy | Reiterates | $20 | +87.27% | Aug 12, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $35 | Buy | Maintains | $35 | +227.72% | Aug 7, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $24 → $23 | Buy | Maintains | $24 → $23 | +115.36% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
153.29M
from 106.47M
Increased by 43.97%
Revenue Next Year
177.70M
from 153.29M
Increased by 15.93%
EPS This Year
1.17
from 1.35
Decreased by -13.58%
EPS Next Year
1.08
from 1.17
Decreased by -7.71%
EPS and Forward PE are based on non-GAAP adjusted numbers.